Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by The University of Hong Kong
Information provided by (Responsible Party):
The University of Hong Kong Identifier:
First received: October 4, 2011
Last updated: September 6, 2015
Last verified: September 2015

October 4, 2011
September 6, 2015
May 2010
December 2016   (final data collection date for primary outcome measure)
Change in coronary artery calcium score and heart valve calcium score [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01447368 on Archive Site
  • Change in aortic pulse wave velocity [ Time Frame: week 24 and wk 52 ] [ Designated as safety issue: No ]
  • change in parathyroid gland size (cinacalcet treatment arm only) [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • change in left ventricular mass index [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • change in left ventricular volume and function [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • change in bone mineral density at forearm, spine and femur [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • change in insulin resistance index [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • Change in subjective global assessment [ Time Frame: wk 24 and 52 ] [ Designated as safety issue: No ]
  • change in lean muscle mass [ Time Frame: wk 52 ] [ Designated as safety issue: No ]
  • change in resting energy expenditure [ Time Frame: wk 24 and wk 52 ] [ Designated as safety issue: No ]
  • change in intact parathyroid hormone (iPTH) level [ Time Frame: Wk 12, 24, 36 and 52 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
Comparison of Medical (Oral Cinacalcet) Therapy Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Study
We propose a pilot, prospective randomized controlled study with the primary objective to evaluate and compare medical treatment of SHPT, namely oral cinacalcet versus surgical treatment, that is, parathyroidectomy with forearm autografting, on the progression of coronary artery and valvular calcification in endstage renal disease patients over 12 months. The change in arterial stiffening and bone mineral density as well as nutritional status will be evaluated as secondary objectives of this study.
Patients with severe secondary hyperparathyroidism (SHPT) are frequently complicated with vascular calcification. There is some suggestion that subtotal parathyroidectomy may reduce or stabilize vascular calcium scores in dialysis patients. Experimental data suggests that SHPT plays an important role in mediating uraemic arterial disease and that parathyroidectomy largely prevented the development of calcification. Cinacalcet has emerged as a novel therapy for the treatment of SHPT and has been shown to reduce the need for surgical parathyroidectomy. However, their effects on vascular and bone status have not been evaluatedand compared with parathyroidectomy.
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
  • Kidney Failure
  • Secondary Hyperparathyroidism
  • Vascular Diseases
Drug: Cinacalcet
oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
Other Name: Regpara
  • Experimental: Cinacalcet treatment
    Intervention: Drug: Cinacalcet
  • Active Comparator: Surgical parathyroidectomy
    Intervention: Drug: Cinacalcet
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2017
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. ESRD patients on long-term peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels > 800pg/mL.
  2. Patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.
  3. Patients with age between 18 - 75 years.

Exclusion Criteria:

  1. Patients with background valvular heart disease
  2. Patients who are unfit for general anaesthesia
  3. Patients with acute myocardial infarction within recent two months
  4. Patients with poor general condition
  5. Patients with plans for living related kidney transplant within 1 year
  6. Patients with previous history of parathyroidectomy
  7. Patients with underlying malignancy
  8. Patients with hepatic dysfunction
18 Years to 75 Years   (Adult, Senior)
Contact: Angela YM Wang, MD, PhD 22554949
Hong Kong
Not Provided
Not Provided
The University of Hong Kong
The University of Hong Kong
Not Provided
Principal Investigator: Angela YM Wang, MD, PhD University of Hong Kong, Queen Mary Hospital
The University of Hong Kong
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP